NIPRO Receives FDA 510(k) Clearance, ELISIO™-HX Dialyzer to Enter the U.S. Market
Osaka, Japan — NIPRO CORPORATION announced on July 30, 2026, that its ELISIO-HX dialyzer has received FDA 510(k) clearance from the U.S. (effective July 28, 2026), thereby introducing its HDs therapy to the United States. HDs is an innovative solution developed by NIPRO in the expanded hemodialysis field, aimed at enhancing the removal of middle- and large-molecular-weight toxins using existing dialysis infrastructure and clinical workflows.
Osaka, Japan, July 30, 2026 - NIPRO CORPORATION announced that its ELISIO-HX dialyzer has received 510(k) clearance from the U.S. Food and Drug Administration (FDA), effective July 28, 2026. This approval marks the official entry of NIPRO's HDs therapy (hemodialysis based on super high-flux membranes) into the U.S. market. HDs is an innovative solution introduced by NIPRO in the field of Expanded Hemodialysis (HDx), designed to provide medical professionals with a practical approach to enhance the therapeutic outcomes of hemodialysis without altering existing dialysis infrastructure and established clinical workflows.
Expanded Hemodialysis: Clearing a Broader Range of Middle and Large Molecular Toxins
Expanded hemodialysis is a hemodialysis approach designed to go beyond the limitations of traditional high-flux dialysis, with the core goal of more effectively removing larger middle-molecular toxins from the body. The HDs therapy combines the ELISIO-HX dialyzer with NIPRO's proprietary membrane technology, enhancing the removal capacity of middle molecules while maintaining full compatibility with routine hemodialysis practices.
In the United States, hemodialysis remains a cornerstone of treatment for patients with end-stage kidney disease. Despite evolving treatment standards, there remains a critical clinical need to remove a broader spectrum of uremic toxins, including larger middle molecules associated with complications of chronic kidney disease. ELISIO-HX was developed to address this clinical gap, with a design that balances broad patient applicability and convenient integration into routine dialysis care.
Making Expanded Hemodialysis More Accessible
At the core of HDs is the ELISIO-HX dialyzer, which features NIPRO's proprietary super high-flux membrane technology. This membrane has a highly controlled and precisely engineered pore structure that expands the removal spectrum of middle and large molecules while maintaining albumin retention - which is crucial for protecting the patient's nutritional status.
This precisely engineered membrane enables medical professionals to enhance the quality of dialysis treatment while remaining fully compatible with traditional hemodialysis systems. Since ELISIO-HX can be seamlessly integrated into existing dialysis infrastructure and clinical workflows, healthcare facilities can adopt HDs therapy without the need to purchase new dialysis machines or fundamentally change the way dialysis is delivered.
"Innovation delivers its greatest value when integrated into everyday clinical practice," said Tsuyoshi Yamazaki, President and CEO of NIPRO CORPORATION. "Our goal is to enable more patients to benefit from enhanced hemodialysis. Through ELISIO-HX and its proprietary super high-flux membrane technology, HDs empowers medical professionals to improve dialysis outcomes using existing infrastructure and expertise. The FDA clearance marks a significant step in our journey to bring this therapy to patients across the United States."
Expanding on Global Clinical Experience
The entry of HDs into the U.S. market builds on the clinical and real-world experience of ELISIO-HX accumulated in Japan, Europe, and Latin America, which has demonstrated its applicability across diverse healthcare settings.
"Our experience across multiple regions has shown that HDs can be successfully integrated into routine dialysis care," said Goichi Miyazumi, President of NIPRO's Global Medical Business Division. "Launching ELISIO-HX in the United States is another important step in making advanced dialysis technology accessible to more patients while supporting medical professionals in delivering high-quality care."
Benefiting More U.S. Dialysis Patients
The United States has one of the largest populations of maintenance hemodialysis patients in the world. With FDA clearance of ELISIO-HX, NIPRO can now introduce HDs into this important market, offering dialysis providers an additional option within the expanded hemodialysis framework that can be seamlessly integrated into existing care models.
By combining proprietary membrane engineering with broad patient applicability and compatibility with routine hemodialysis systems, HDs enables healthcare providers to extend the benefits of expanded hemodialysis to a wider patient population without adding complexity to routine clinical practice.
With the 510(k) clearance, NIPRO will immediately initiate the commercialization of ELISIO-HX in the United States. NIPRO will work closely with medical professionals to support the smooth integration of HDs into routine clinical practice.
This milestone reflects NIPRO's commitment to developing practical solutions that help medical professionals deliver better care to more patients. By enhancing access to enhanced dialysis care, NIPRO continues to fulfill its corporate mission of helping people live longer and better.
About NIPRO
NIPRO is a global healthcare company dedicated to improving patient outcomes through innovative medical technologies, pharmaceutical solutions, and regenerative medicine. Committed to helping people live longer and better, NIPRO collaborates with healthcare professionals worldwide to provide safe, reliable, and practical solutions that advance patient care.
